Psilocybin’s ‘efficacy and safety’ for bipolar II depression demonstrated by American medical association study
“12 patients met both response and remission criteria” at the end of a 12-week study period, the trial found, meaning that measures of the diagnosis had dropped by more than half and fell below a minimum threshold.
Results… published by the American Medical Association “suggest efficacy and safety” of psilocybin-assisted psychotherapy for treatment of bipolar II disorder, a mental health condition often associated with debilitating and difficult-to-treat depressive episodes. A separate study from the American Medical Association (AMA) came out in August [2023] showing that people with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin.
Original Article (Marijuana Moment):
Psilocybin’s ‘efficacy and safety’ for bipolar II depression demonstrated by American Medical Association Study
Artwork Fair Use: Justin Paulin
